[ANMCO/SIC/SICI-GISE/SICCH Consensus document: Clinical approach to pharmacological pretreatment for patients undergoing myocardial revascularization].
The wide availability of drugs effective in reducing cardiovascular events and the use of myocardial revascularization have greatly improved the prognosis of patients with coronary artery disease. However, the combination of antithrombotic drugs to be administered before the exact knowledge of the coronary anatomy and before the consequent therapeutic strategy can, on one hand, allow to anticipate an optimal treatment but, on the other hand, may expose the patient to a bleeding risk not always necessary. In patients with ST-elevation acute coronary syndrome with an indication to primary angioplasty, the administration of unfractionated heparin and aspirin is considered the pre-procedural standard treatment. The upstream administration of an oral P2Y12 inhibitor, even if not supported by randomized controlled trials, appears reasonable in view of the very high likelihood of treatment with angioplasty. In patients with non-ST elevation acute coronary syndrome, in which it is not always chosen an invasive strategy, the occurrence of bleeding can significantly weigh on prognosis, even more than the theoretical benefit of pretreatment. Fondaparinux is the anticoagulant with the most favorable efficacy/safety profile. Antiplatelet pretreatment must be selective, guided by the ischemic risk conditions, the risk of bleeding and the time schedule for coronary angiography.In patients with stable coronary artery disease, generally treated with aspirin, pretreatment with clopidogrel is advisable in case of already scheduled angioplasty, and it appears reasonable in case of high likelihood, at least in patients at low bleeding risk. In patients candidate to surgical revascularization, aspirin is typically maintained and the oral P2Y12-inhibitor discontinued, with i.v. antiplatelet drug bridging in selected cases.Anti-ischemic drugs are useful in controlling symptoms, but they have no specific indications with regard to revascularization procedures. Statins showed protective effects on periprocedural damage and late clinical events, when administered early. Although randomized data are lacking, it seems reasonable their pre-procedural administration, due to potential advantages without significant adverse effects.
U.O.C. Cardiologia Interventistica, Ospedale SS. Annunziata, Cosenza.
Roberto
R
Caporale
U.O. Cardiologia, A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo.
Giovanna
G
Geraci
U.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania.
Michele Massimo
MM
Gulizia
U.O.C. Cardiologia e Cardiologia Interventistica, Policlinico "Tor Vergata", Roma.
Mauro
M
Borzi
U.O.C. Cardiologia-UTIC, Presidio Ospedaliero San Filippo Neri, Roma.
Furio
F
Colivicchi
U.O. Cardiologia, Azienda Ospedaliera Universitaria di Parma, Parma.
Alberto
A
Menozzi
Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo.
Giuseppe
G
Musumeci
Cardiologia Interventistica-UTIC, A.O. G. Rummo, Benevento.
Marino
M
Scherillo
U.O. Cardiologia, A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo.
Antonietta
A
Ledda
Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari, Università degli Studi, Padova.
Giuseppe
G
Tarantini
U.O. Cardiochirurgia, Istituto Humanitas Gavazzeni, Bergamo.
Piersilvio
P
Gerometta
S.C. Cardiologia, Nuovo Ospedale Versilia, Lido di Camaiore (LU).
Giancarlo
G
Casolo
Cardiologia Interventistica-UTIC, A.O. G. Rummo, Benevento.
Dario
D
Formigli
U.O.C. Cardiologia e Cardiologia Interventistica, Policlinico "Tor Vergata", Roma.
Francesco
F
Romeo
U.O. Cardiochirurgia, Ospedale Policlinico S. Orsola-Malpighi, Bologna.
Roberto
R
Di Bartolomeo
D006801:Humans; D054058:Acute Coronary Syndrome / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D000077425:Fondaparinux; D006493:Heparin / Q000008:administration & dosage; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007558:Italy; D009204:Myocardial Revascularization / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D011300:Preoperative Care / Q000379:methods; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
D000925:Anticoagulants; D001241:Aspirin; D000077144:Clopidogrel; D000077425:Fondaparinux; D006493:Heparin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D011134:Polysaccharides; D013988:Ticlopidine